Hypera Stock

Hypera Net Debt / EBITDA

The Net Debt to EBITDA of Hypera (HYPE3.SA) as of Aug 7, 2026 is 3.96. In the previous year, Net Debt to EBITDA was 3.17 — a change of 24.87% (higher).

Net Debt / EBITDA

3.96

YoY

24.87%

Last updated:

Net Debt to EBITDA of Hypera is 2026 3.96 . Net Debt to EBITDA of Hypera was 2025 3.17 . It decreases by 24.87% higher compared to the previous year.
Access this data via the Eulerpool API

Hypera Stock analysis

What does Hypera do? Hypera SA is a Brazilian pharmaceutical company founded in 2001, specializing in the development, production, and distribution of drugs, generics, medical devices, and cosmetic products primarily for the Brazilian healthcare industry. Hypera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hypera stock

Net Debt to EBITDA of Hypera is 3.96 in 2026.

Net Debt to EBITDA of Hypera changed from 3.17 to 3.96, representing a 24.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Hypera since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Hypera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Hypera

All Key Metrics — Hypera